CORDIS
EU research results

CORDIS

English EN

EPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE

Objective

CLINICAL NEED
Every year in the EU ~45,300 and 330,000 women are diagnosed with ovarian and breast cancer respectively & 28,800 and 90,000 of these two groups of women will die as a consequence of these diseases. Currently there are no tools available that allow for:
a) Effective screening of ovarian and/or breast cancer of sufficient sensitivity and specificity to avoid potential over-diagnosis, or;
b) Stratification of patients into optimal personalised therapy regimes in ovarian/breast cancer.

EpiFemCare ADVANCES
Progress in personalised cancer medicine will only be possible with the development of bioassays involving the analysis of easy accessible biomaterials that contain stable target molecules reflective of disease. We will establish and clinically validate a series of blood tests based upon DNA methylation technology that will facilitate both early detection and prediction of therapeutic outcome in breast and ovarian cancer.

CONSORTIUM
Our pan-European academic-industrial consortium demonstrates diverse clinical, scientific & industrial expertise. We have access to the latest state of the art technologies and, integrally, the best available cohort and clinical trial sample sets required to ensure the success of the EpiFemCare program. GATC-Biotech and Genedata are Europe’s leading providers of DNA sequencing and bioinformatics for biomarker development and have developed serum DNA based prenatal tests. The clinical partners have access to unique cohort and clinical samples collected from >200,000 women well in advance of disease (UK Collaborative Trial of Ovarian Cancer Screening) or before and during treatment (SUCCESS Trial).

IMPACT
As a result of refined and improved patient stratification, EpiFemCare will:
- Reduce the late stage presentation of ovarian & breast cancer by 50%
- Reduce the requirement for 50% of breast cancer patients to have adjuvant therapies
- Reduce female cancer related fatalities as well as treatment-related morbidity by 20%
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY COLLEGE LONDON

Address

Gower Street
Wc1e 6bt London

United Kingdom

Activity type

Other

EU Contribution

€ 2 052 712

Administrative Contact

Greta Borg-Carbott (Ms.)

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

Eurofins Genomics Europe Sequencing GmbH

Germany

EU Contribution

€ 2 136 106

GENEDATA AG

Switzerland

EU Contribution

€ 852 245

EURAM LIMITED

United Kingdom

EU Contribution

€ 354 344

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 249 932

UNIVERZITA KARLOVA

Czechia

EU Contribution

€ 230 048

Project information

Grant agreement ID: 305428

Status

Closed project

  • Start date

    1 November 2012

  • End date

    30 April 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 633 928,71

  • EU contribution

    € 5 875 387

Coordinated by:

UNIVERSITY COLLEGE LONDON

United Kingdom